Retrospective epidemiological study of Latin American patients with transfusional hemosiderosis: The first Latin American epidemiological study in iron overload - the RELATH study

Hematology

Volumn 16, Issue 5, 2011, Pages 265-273

  Lobo, Clarisse ^a   Ǎngulo, Ivan L ^b   Aparicio, Lidia R ^c   Drelichman, Guillermo I ^d   Zanichelli, Maria A ^e   Cancado, Rodolfo ^f  

^a Neurolife Cerebrospinal Fluid Laboratory   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Servicio de Hematologia   (Panama)

^d HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^e HOSPITAL BRIGADEIRO   (Brazil)

^f FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

Author keywords

Chelation therapy; Iron overload; Myelodysplastic syndromes; Pediatrics; Sickle cell; Thalassemia

Indexed keywords

FERRITIN; HEMOGLOBIN;

ADULT; ARTHROPATHY; ARTICLE; CHELATION THERAPY; CHILD; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE REGISTRY; ENZYME DEFECT; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; GROWTH RETARDATION; HEMOSIDEROSIS; HUMAN; HYPERGLYCEMIA; HYPERPIGMENTATION; HYPOCALCEMIA; HYPOGONADISM; HYPOTHYROIDISM; IRON OVERLOAD; LATIN AMERICAN MEDICINE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SICKLE CELL ANEMIA; THALASSEMIA MAJOR; THERAPY EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; CHILD, PRESCHOOL; ENDOCRINE SYSTEM DISEASES; FEMALE; FERRITINS; HEART DISEASES; HEMOGLOBINS; HEMOSIDEROSIS; HUMANS; IRON CHELATING AGENTS; LATIN AMERICA; LIVER DISEASES; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; SKIN PIGMENTATION; YOUNG ADULT;

EID: 80052555480     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453311X13085644680302     Document Type: Article

References (43)

1. Cazzola M, De Stefano P, Ponchio L, Locatelli F, Beguin Y, Dessi C, et al. Relationship between transfusion regimen and suppression of erythropoiesis in betathalassaemia major. Br J Haematol 1995;89:473-8.
2. Cazzola M, Borgna-Pignatti C, Locatelli F, Ponchio L, Beguin Y, De Stefano P. A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. Transfusion 1997;37:135-40.
3. Porter JB. Practical management of iron overload. Br J Haematol 2001;115:239-52.
4. Schafer AI, Cheron RG, Dluhy R, Cooper B, Gleason RE, Soeldner JS, et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981;304:319-24.
5. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999;341:1986-95.
6. Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci 1998;850:227-31.
7. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, et al. Survival and causes of death in thalassaemia major. Lancet 1989;2:27-30.
8. Aessopos A, Farmakis D, Karagiorga M, Voskaridou E, Loutradi A, Hatziliami A, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 2001;97:3411-6.
9. Batra AS, Acherman RJ, Wong WY, Wood JC, Chan LS, Ramicone E, et al. Cardiac abnormalities in children with sickle cell anemia. Am J Hematol 2002;70:306-12.
10. Greenberg PL. Myelodysplastic syndromes: iron overload consequences and current chelating therapies. J Natl Compr Canc Netw 2006;4:91-6.
11. Beutler E, Hoffbrand AV, Cook JD. Iron deficiency and overload. Hematology (Am Soc Hematol Educ Program) 2003:40-61.
12. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-73.
13. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000;355:2051-2.
14. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994;331:574-8.
15. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998;339:417-23.
16. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003;361:1597-602.
17. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;107:3455-62.
18. Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007;136:501-8.
19. Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Damanhouri G, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with betathalassaemia: the ESCALATOR study. Eur J Haematol 2009;82:458-65.
20. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99.
21. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
22. Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000;343:327-31.
23. Iron overload disorders among Hispanics-San Diego, CA, USA, 1995. MMWR Morb Mortal Wkly Rep 1996;45:991-3.
24. Araújo A, Drelichman G, Cançdo RD, Watman N, Magalhães SM, Duhalde M, et al. Management of transfusional iron overload in Latin America: current outlook and expert panel recommendations. Hematology 2009;14:22-32.
25. Penchaszadeh VB. Community genetics in Latin America: challenges and perspectives. Community Genet 2000;3:124-7.
26. Penchaszadeh VB, Beiguelman B. Medical genetic services in Latin America: report of a meeting of experts. Rev Panam Salud Publica [document on the internet]. 1998, vol. 3, no. 6 [cited 2009 Oct 22]. p. 409-420. Available from: http://www.scielosp.org/scielo.php?script5sci_arttext&pid5S1020-49891998000600013&lng5en&nrm5iso
27. Roldan A, Gutierrez M, Cygler A, Bonduel M, Sciuccati G, Torres AF. Molecular characterization of b-thalassemia genes in an Argentine population. Am J Hematol 1997;54:179-82.
28. Loureiro MM, Rozenfeld S, Carvalho MS, Portugal RD. Factors associated with hospital readmission in sickle cell disease. BMC Blood Disord 2009;9:2.
29. Cuéllar-Ambrosi F, Mondragón MC, Gigueroa M, Préhu C, Galactéros F, Ruiz-Linares A. Sickle cell anemia and b-globin gene cluster haplotypes in Colombia. Hemoglobin 2000;24:221-5.
30. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339:5-11.
31. Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005;353:2769-78.
32. Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol 2001;38:30-6.
33. Vichinsky E, Butensky E, Fung E, Hudes M, Theil E, Ferrell L, et al. Comparison of organ dysfunction in transfused patients with SCD or b Thalssemia. Am J Hematol 2005;80:70-4.
34. Fung EB, Harmatz PR, Lee PD, Milet M, Bellevue R, Jeng MR, et al. Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol 2006;135:574-82.
35. Fung EB, Harmatz PR, Milet M, Balasa V, Ballas SK, Casella JF, et al. Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. Transfusion 2008;48:1971-80.
36. Fernandes JL, Fabron A, Verissimo M. Early cardiac iron overload in children with transfusion-dependent anemias. Haematologica 2009;94:1776-7.
37. Low LC. Growth, puberty and endocrine function in betathalassemia major. J Pediatr Endocrinol Metabl 1997;10:175-84.
38. Gulati R, Bhatia V, Argarwal SS. Early onset of endocrine abnormalities in beta-thalssemia major in a developing country. J Pediatr Endocrinol Metab 2000;13:651-6.
39. Soliman AT, el-Zalabany M, Amer M, Ansari BM. Growth and pubertal development in transfusion-dependent children and adolescents with thalassemia major and sickle cell disease: a comparative study. J Trop Pediatr 1999;4591:23-30.
40. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-93.
41. Davis BA, Porter JB. Long-term outcome of continuous 24- hour deferoxamine infusion via indwelling intravenous catheters in high risk beta-thalassemia. Blood 2000;95:1229-36.
42. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996;95:26-36.
43. Adamkiewicz TV, Abboud MR, Paley C, Olivieri N, Kirby-Allen M, Vichinsky E, et al. Serum ferritin level changes in children with sickle cell disease on chronic blood transfusions are non-linear, and are associated with iron load and liver injury. Blood 2009;114:4632-8.